Eight Advisory supported Motion Equity Partners on its investment in Axience Group
The Eight Advisory team provided financial due diligence services to Motion Equity Partners on its investment in Axience Group, acquiring a stake alongside its founder and CEO, Laurent Flaus.
Axience Group is a leading French laboratory specialising in the development and commercialisation of veterinary pharmaceuticals. Founded in 2001, the Group develops and commercializes pharmaceutical and OTC products primarily for pets, under its two brands Axience and Anidev.
The aim of this strategic partnership between Motion Equity Partners and Axience is to accelerate the Group’s development and expand its presence in Europe.
Eight Advisory team members supporting on this transaction:
- Boris Bignon, Partner
- Noufissa Benjelloun, Senior Manager
Corporate News
Rolling Forecast: Cash flow forecasts and budgeting finally converging?
13 Jun 2025
Read more
Deals
Eight Advisory and Eight Advisory Avocats assisted the Delabie group in its acquisition of the KWC Professional group
13 Jun 2025
Read more
Corporate News
Defence: France launches nationwide drive to arm its defence industry with capital
11 Jun 2025
Read more
Deals
Eight Advisory supported Harmonie Mutuelle on its acquisition of NoveoCare
10 Jun 2025
Read more